mirtazapine 45 MG Disintegrating Oral Tablet [Remeron]
mirtazapine
RxCUI: 752871
What the CMS Formulary Data Shows for mirtazapine 45 MG Disintegrating Oral Tablet [Remeron]
Per the CMS 2026 Part D formulary file, mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] (RxNorm concept RXCUI 752871, generic name mirtazapine) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.
Real-world access to mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,551,607 Part D beneficiaries filled mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] in 2023, with total plan-and-beneficiary spending of $176,432,051 and an average per-beneficiary annual cost of $113.71. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 2
- Coverage rate
- 0%
- Tier range
- Tier 1, Preferred Generic
- Average tier
- Tier 1, Preferred Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,551,607
- Total spending
- $176,432,051
- Avg per beneficiary
- $113.71
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering mirtazapine 45 MG Disintegrating Oral Tablet [Remeron]
2 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Hamaspik Medicare Choice (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $0 | NY |
| Hamaspik Medicare Select (HMO D-SNP) | HAMASPIK, INC. | T1 | No | $34.50 | NY |
Frequently Asked Questions
Is mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] covered by Medicare Part D?
Yes, mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] is covered by 2 Medicare Part D plans (0% of all Part D formularies).
What tier is mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] on Medicare Part D plans?
mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.
Does mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] require prior authorization?
0% of Part D formularies require prior authorization for mirtazapine 45 MG Disintegrating Oral Tablet [Remeron]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on mirtazapine 45 MG Disintegrating Oral Tablet [Remeron]?
In 2023, total Medicare Part D spending on mirtazapine 45 MG Disintegrating Oral Tablet [Remeron] was $176,432,051, covering 1,551,607 beneficiaries. The average spend per beneficiary was $113.71.
Read our methodology - how this data is sourced, computed, and verified.